呲仑帕奈治疗癫痫的效果
This study was a multicenter, double-blind clinical study of patients ≥12 years of age with PGTC epilepsy or IGE; these patients were randomly assigned to receive placebo or perampanel during a 4-week dose titration period (perampanel was titrated from 2 mg/d to 8 mg/d or the patient's highest tolerated dose) and a 13-week maintenance period.
The primary endpoint was change in PGTC attack frequency (patient treatment period compared with baseline) assessed every 28 days. The key secondary endpoint was a 50% response rate in patients with PGTC epilepsy (a ≥50% reduction in the frequency of PGTC epilepsy compared with baseline during the maintenance phase of treatment). During the study, new adverse events from treatment will be monitored throughout the study.
This study concluded that combination treatment with perampanel improved seizure control in patients with drug-refractory PGTC and was well tolerated. This study provides level I evidence for perampanel combination therapy in the treatment of PGTC epilepsy.
It was approved to be launched in China on September 29, 2019, and has now been included in the national medical insurance to provide everyone with government discounts to reduce the financial burden. But even after medical insurance, the price of parampanel remains high, prohibiting many families. However, according to Medical Companion Brigade, parampanel is more suitable for long-term use by patients and more cost-effective than other versions. Since the exchange rate has been in a state of fluctuation for a long time, the price fluctuates with the exchange rate and is not static. For more information about Parapanel, please contact Medical Companion Travel for details.
Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.
Recommended related articles:
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)